ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RNAC / news
INO (24) AKBA (49) ADCT (36) PRQR (44) ⌘ Pro Terminal →

Why RNAC Stock dropped -2.31% Today — RQD Quant Desk Flash

$6.34 -2.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.30

Cartesian Therapeutics Inc. (RNAC) carries a Roarable Rating of E (Strong Sell) with 15/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $191.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RNAC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RNAC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cartesian Therapeutics Inc. (NASDAQ: RNAC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 15/100 at a spot price of $6.34 (-2.31% 1D, market cap $191.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RNAC ranks #1013 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RNAC compare to INO and AKBA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNAC carries a Roarable E (15/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INO (Inovio Pharmaceuticals Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $195.4M) and AKBA (Akebia Therapeutics Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC 85.0%, cap $196.3M). Among the 5-stock peer group, RNAC leads on earnings multiple (N/A) while AKBA leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RNAC?
▼

Per RNAC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001453687), Cartesian Therapeutics Inc. generated $400.0K in revenue (-99.0% YoY), -$130.3M in net income, and -$79.4M in free cash flow against $296.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.30 (-0.61%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (15/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510015
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (3)Whales (3)SEC (3)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-19.4% Base Target
$12 Bull$5 Base$4 Bear
📬 FREE RNAC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNAC)Realized 20D OHLCV Swing Band: ±12.2%
Deterministic 5-Pillar Attribution (15/100 Composite)
🔍 WHY RNAC SCORES 15/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+5/20 pts (33% of score)

FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 40.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
15
Grade E$6.34+1.3% Next Q
Q2 (-2Q)
16
Grade E$6.42+4.2% Next Q
Q3 (-1Q)
18
Grade E$6.69-5.2% Next Q
Current
15
Grade E$6.34-12.9% Hist 90D α
Trajectory: E (15) → E (15)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RNAC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RNAC currently carries a cautious 15/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.51) and Max Pain ($6.66) forces dealer call-delta covering toward $11.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNAC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RNAC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 18%NO 82%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why RNAC Stock dropped -2.31% Today — RQD Quant Desk Flash

Cartesian Therapeutics Inc. (RNAC) dropped -2.31% to $6.34, trading at 14% of its 52-week range ($5.6 – $11). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 14% of its 52-week range ($5.6 – $11) with RSI-14 at 40.2 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.2% around $6.34 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RNAC Headlines & Catalysts
MARKET WIRETradingKey • 2d ago
Most Active Stocks Today: U.S. Market

TradingKey report covering Cartesian Therapeutics Inc. (RNAC) market action, institutional positioning, and fundamental catalysts.

MARKET WIREYahoo • 11h ago
Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates

Amgen (AMGN) delivered earnings and revenue surprises of +12.37% and +4.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNAC)

  • ✓Walkthrough of RNAC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RNAC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.21%📐 HORIZONTAL RANGE
2026-11-04O $6.49H $6.49L $6.34C $6.34VOL 114.7K
RES: $10.74SUP: $5.74SMA50: $7.51SMA200: $7.63
$11.37$9.85$8.33$6.82$5.30RES $10.74SUP $5.74$6.342026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNAC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNAC Butterfly Map → + Track RNAC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RNAC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNAC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RNAC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNAC)

Health Care Rank #1013 of 1015 ⚔️ INO vs RNAC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNAC vs. INO, AKBA, ADCT, PRQR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cartesian Therapeutics Inc. (RNAC) ranks #1013 by composite RQD confidence (15/100, grade E) and #579 by equity capitalization ($191.8M). Within this direct 5-issuer industry benchmark cohort, RNAC leads on earnings valuation at N/A trailing P/E, while AKBA leads on capital efficiency and profitability with 85.0% ROIC and 83.3% gross margin. AKBA currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with RNAC at 15/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RNAC ACTIVE
Cartesian Therapeutics Inc.
E 15/100 — — -35.0% -2.31% $191.8M Benchmark Subject
INO
Inovio Pharmaceuticals Inc.
E 24/100 — — -35.0% +213.75% $195.4M /ino-vs-rnac →
AKBA
Akebia Therapeutics Inc.
D 49/100 — 83.3% 85.0% +0.27% $196.3M /akba-vs-rnac →
ADCT
ADC Therapeutics SA
D- 36/100 — 92.9% -35.0% +0.65% $196.6M /adct-vs-rnac →
PRQR
ProQR Therapeutics N.V.
D 44/100 — — — -5.04% $186.3M /prqr-vs-rnac →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001453687 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cartesian Therapeutics Inc. (RNAC) reported GAAP revenue of $400.0K (-99.0% vs. FY2024 revenue of $38.3M , and -98.5% cumulative change since FY2023) , GAAP net income of -$130.3M, operating cash flow of -$73.9M, and free cash flow of -$79.4M (-142.3% YoY). On the balance sheet, RNAC closed FY2025 with $296.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $400.0K -$130.3M -$73.9M -$79.4M $296.4M $0
FY2024 (FY) 2024-12-31 $38.3M -$77.4M -$23.7M -$32.8M $435.0M —
FY2023 (FY) 2023-12-31 $26.0M -$219.7M -$51.2M -$51.2M — —

3. RNAC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNAC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cartesian Therapeutics Inc. (NASDAQ: RNAC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 15/100 at a spot price of $6.34 (-2.31% 1D, market cap $191.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RNAC ranks #1013 in composite RQD confidence.

How does RNAC compare to INO and AKBA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNAC carries a Roarable E (15/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INO (Inovio Pharmaceuticals Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $195.4M) and AKBA (Akebia Therapeutics Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC 85.0%, cap $196.3M). Among the 5-stock peer group, RNAC leads on earnings multiple (N/A) while AKBA leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RNAC?

Per RNAC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001453687), Cartesian Therapeutics Inc. generated $400.0K in revenue (-99.0% YoY), -$130.3M in net income, and -$79.4M in free cash flow against $296.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RNAC trading relative to its 50-day, 200-day, and 52-week technical levels?

RNAC last traded at $6.34 (-2.31% on volume of 114,734 shares), positioning the stock -15.58% below its 50-day simple moving average ($7.51) and -16.91% below its 200-day simple moving average ($7.63). Across its 52-week range of $5.60 to $11.00, RNAC sits at the 13.7% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.2% ($5.57 to $7.11).

Direct Sub-Reports: RNAC RQD Cockpit RNAC 12M Forecast RNAC Earnings & Move RNAC Dividends & DRIP RNAC Insiders & 13F RNAC Whale Options RNAC Profit Sankey RNAC News & Why
ROARABLE RATING BRIEF • RQD 15/100 (E) ✓ SEC XBRL & RQD VERIFIED

RNAC — Cartesian Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cartesian Therapeutics Inc. (RNAC) earns a live Roarable RQD composite score of 15/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $6.34 (-2.31% 1D, market capitalization $191.8M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cartesian Therapeutics Inc. (RNAC) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile gives a market capitalization of $0.2B. The financials show reported revenue of $0.4M for FY 2025, down from $38.3M for FY 2024 ().

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cartesian Therapeutics Inc. (RNAC) reported $400.0K in annual revenue (up from $38.3M in FY2024, -99.0% YoY) and -$130.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($26.0M revenue, -$219.7M net income) through FY2025, RNAC scaled operating cash flow to -$73.9M and free cash flow to -$79.4M, backed by $296.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 15/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $5.60 – $11.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), RNAC carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can RNAC sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $400.0K and free cash flow of -$79.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RNAC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RNAC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cartesian Therapeutics Inc. (RNAC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RNAC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RNAC Bull vs. Bear Conversation Board — What's Your Call at $6.34?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RNAC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RNAC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $7.79 (+20.0%)
📌 Pinned Debate

Institutional flow scores 11 of 20 in the Roarable RQD rating, the strongest pillar, indicating some positioning support beyond fundame

Long RNAC at $6.49 targeting $7.79. Institutional flow scores 11 of 20 in the Roarable RQD rating, the strongest pillar, indicating some positioning support beyond fundamentals.. Institutional whale score is 3/20 and the risk/reward vs. the $5.60 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $6.49 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $5.39 (-16.9%)
Spot @ $6.49

ROIC of -35% and an Altman Z-Score of 0.2 show weak cash returns and elevated balance-sheet distress risk, with FY 2025 revenue down to

Fading this rally in RNAC at $6.49. ROIC of -35% and an Altman Z-Score of 0.2 show weak cash returns and elevated balance-sheet distress risk, with FY 2025 revenue down to $0.4M from $38.3M.. With a beta of 1.0 and the stock sitting at $6.49 (52-wk range $5.60–$11.00), the easy multiple expansion is already priced in.

LIVE TAPE